Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

AHK-Cu vs Rigin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

AHK-Cu and Rigin share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer AHK-Cu has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; AHK-Cu's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

AHK-Cu

Cosmetic Clinical Studies

Rigin

Cosmetic Clinical Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

AHK-Cu Rigin
Class Copper tripeptide (cosmetic) Cosmetic lipopeptide (anti-inflammatory)
Drug class Dermatologic Dermatologic
Mechanism Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp Suppresses IL-6 secretion by fibroblasts; reduces inflammaging
Route Topical Topical
Half-life Topical (no systemic) Topical
Dosage (research) Topical 0.01-0.1% Topical 2-4%
Evidence tier Cosmetic Clinical Studies Cosmetic Clinical Studies
Research depth 3 indexed (PubMed 1 · CT 1 · EPMC 1) 31 indexed (PubMed 15 · CT 0 · EPMC 16)
Availability Cosmetic Cosmetic
Reported risks Skin irritation; theoretical copper issues Minimal

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick AHK-Cu or Rigin?

AHK-Cu and Rigin share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer AHK-Cu has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; AHK-Cu's evidence base is currently denser.

What is the difference between AHK-Cu and Rigin?

AHK-Cu is classed as Copper tripeptide (cosmetic); Rigin is classed as Cosmetic lipopeptide (anti-inflammatory). Reported mechanism: AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp; Rigin, Suppresses IL-6 secretion by fibroblasts; reduces inflammaging. Reported half-life: AHK-Cu, Topical (no systemic); Rigin, Topical. Routes in published studies: AHK-Cu, Topical; Rigin, Topical.

Which has stronger evidence, AHK-Cu or Rigin?

AHK-Cu and Rigin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 3 indexed studies. Rigin is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 31 indexed studies.

Which is more accessible, AHK-Cu or Rigin?

Neither AHK-Cu nor Rigin is an FDA-approved drug. Catalog status: AHK-Cu, Cosmetic; Rigin, Cosmetic.

Are AHK-Cu and Rigin ever combined?

AHK-Cu and Rigin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…